Roche Purchase of Igen Resolves Licensing Dispute, Preserves Technology
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics will retain roughly $400 mil. in annual revenues through the $1.4 bil. acquisition of Origen electrochemilumunescence technology licensor Igen International
You may also be interested in...
Roche closes Igen deal
BioVeris stock commences trading on the Nasdaq exchange Feb. 17 under the symbol "BIOV," following completion of Roche Diagnostic's $1.4 bil. acquisition of Igen International (1"The Gray Sheet" July 28, 2003, p. 5). BioVeris, spun-off from Igen, is based in Gaithersburg, Md. and will be led by former Igen management. The firm will assume the ongoing biodefense, lifescience and clinical diagnostic Igen businesses. Former Igen shareholders received $47.25 in cash from Roche and one share of BioVeris for each Igen share held...
Roche closes Igen deal
BioVeris stock commences trading on the Nasdaq exchange Feb. 17 under the symbol "BIOV," following completion of Roche Diagnostic's $1.4 bil. acquisition of Igen International (1"The Gray Sheet" July 28, 2003, p. 5). BioVeris, spun-off from Igen, is based in Gaithersburg, Md. and will be led by former Igen management. The firm will assume the ongoing biodefense, lifescience and clinical diagnostic Igen businesses. Former Igen shareholders received $47.25 in cash from Roche and one share of BioVeris for each Igen share held...
Enzo Breach-Of-Contract Suit Against Affymetrix Seeks $500 Mil. In Damages
Gene chip developer Affymetrix says it is "prepared to fully meet" customer needs through existing inventories following a breach-of-contract suit filed by supplier Enzo Biochem